Skip to main content
Young Women with Breast Cancer May Safely Pause Endocrine Therapy to Pursue Pregnancy
By Patricia Stewart
Women's Health, Breast Cancer, SABCS 2022 Highlights, SABCS Highlights
March 2023, Vol 13, No 3
Young women with early-stage, hormone receptor (HR)-positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial. Read More ›
PARP Inhibitors Have Acceptable Toxicity Profiles and Have Shown Efficacy in Treatment of Ovarian Cancer
Women's Health
Web Exclusives
Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer. Read More ›
Olaparib plus Bevacizumab Has Been Approved as Maintenance Therapy for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Women's Health
Web Exclusives
Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab. Read More ›
Coping Strategies Utilized by Women with Ovarian Cancer During the COVID-19 Pandemic
Women's Health
Web Exclusives
Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies. Read More ›
Alternatives to Intravenous Therapies for Ovarian Cancer During the COVID-19 Era
Women's Health
Web Exclusives
Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy. Read More ›
Fundamentals of Creating a Telemedicine Program for Reconstructive Breast Surgery
Women's Health
Web Exclusives
Telemedicine may play a critical role by creating pathways for overcoming obstacles to healthcare access, particularly for breast cancer reconstruction. Read More ›